Dimensional Fund Advisors LP Buys 8,567 Shares of Sanara MedTech Inc. (NASDAQ:SMTI)

Dimensional Fund Advisors LP boosted its position in Sanara MedTech Inc. (NASDAQ:SMTI - Free Report) by 116.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 15,925 shares of the company's stock after acquiring an additional 8,567 shares during the quarter. Dimensional Fund Advisors LP owned 0.18% of Sanara MedTech worth $529,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the company. Wells Fargo & Company MN increased its stake in shares of Sanara MedTech by 53.9% in the 4th quarter. Wells Fargo & Company MN now owns 1,893 shares of the company's stock valued at $63,000 after purchasing an additional 663 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in Sanara MedTech by 127.2% in the third quarter. JPMorgan Chase & Co. now owns 4,058 shares of the company's stock valued at $123,000 after buying an additional 2,272 shares in the last quarter. Barclays PLC grew its position in Sanara MedTech by 323.0% in the third quarter. Barclays PLC now owns 5,731 shares of the company's stock valued at $174,000 after acquiring an additional 4,376 shares during the last quarter. Bank of New York Mellon Corp grew its position in Sanara MedTech by 24.0% in the fourth quarter. Bank of New York Mellon Corp now owns 13,054 shares of the company's stock valued at $433,000 after acquiring an additional 2,528 shares during the last quarter. Finally, Fifth Third Bancorp bought a new position in shares of Sanara MedTech in the fourth quarter worth about $898,000. 8.10% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the stock. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $46.00 price target on shares of Sanara MedTech in a report on Wednesday, March 26th. HC Wainwright raised their target price on shares of Sanara MedTech from $51.00 to $53.00 and gave the company a "buy" rating in a research report on Thursday.

Sanara MedTech Trading Down 1.0%

NASDAQ SMTI traded down $0.32 during trading hours on Monday, reaching $31.18. The company's stock had a trading volume of 13,727 shares, compared to its average volume of 26,104. Sanara MedTech Inc. has a 52 week low of $25.86 and a 52 week high of $39.08. The company has a debt-to-equity ratio of 0.76, a current ratio of 2.23 and a quick ratio of 2.02. The stock has a market cap of $277.13 million, a P/E ratio of -31.49 and a beta of 1.38. The firm has a fifty day simple moving average of $31.06 and a 200-day simple moving average of $33.45.

Sanara MedTech (NASDAQ:SMTI - Get Free Report) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($0.41) EPS for the quarter, missing analysts' consensus estimates of ($0.31) by ($0.10). The business had revenue of $23.43 million for the quarter, compared to analyst estimates of $23.48 million. Sanara MedTech had a negative return on equity of 19.86% and a negative net margin of 10.71%. Equities analysts forecast that Sanara MedTech Inc. will post -1.1 earnings per share for the current fiscal year.

About Sanara MedTech

Sanara MedTech Inc, a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers.